Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

被引：34

作者：

Breccia, Massimo ^{[1
]}

Cimino, Giuseppe ^{[1
]}

Diverio, Daniela ^{[1
]}

Gentilini, Fabiana ^{[1
]}

Mandelli, Franco ^{[1
]}

Lo Coco, Francesco ^{[2
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[2] Univ Tor Vergata, Dept Biopathol, Rome, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 09期

关键词：

acute promyelocytic leukemia; gentuzumab ozogamicin; molecular relapse;

D O I：

10.3324/haematol.11329

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m(2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

引用

页码：1273 / 1274

页数：2

共 11 条

[1]

Diverio D, 1998, BLOOD, V92, P784

[2] Experience with gemtuzumab ozogamycin ("mylotarg"), and all-trans retinoic acid in untreated acute promyelocytic leukemia [J].

Estey, EH ;

Giles, FJ ;

Beran, M ;

O'Brien, S ;

Pierce, SA ;

Faderl, SH ;

Cortes, JE ;

Kantarjian, HM .

BLOOD, 2002, 99 (11) :4222-4224

[3]

HINMAN LM, 1993, CANCER RES, V53, P3336

[4] Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia [J].

Lo-Coco, F ;

Cimino, G ;

Breccia, M ;

Noguera, NI ;

Diverio, D ;

Finolezzi, E ;

Pogliani, EM ;

Di Bona, E ;

Micalizzi, C ;

Kropp, M ;

Venditti, A ;

Tafuri, A ;

Mandelli, F .

BLOOD, 2004, 104 (07) :1995-1999

[5] Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid [J].

Martini, Vincenza ;

Minotti, Clara ;

Breccia, Massimo ;

De Angelis, Gioia ;

Buffolino, Sonia ;

Mariella, Montano ;

Lo-Coco, Francesco ;

Avvisati, Giuseppe ;

Cimino, Giuseppe .

ANNALS OF HEMATOLOGY, 2007, 86 (04) :295-297

[6] P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia [J].

Michieli, M ;

Damiani, D ;

Ermacora, A ;

Geromin, A ;

Michelutti, A ;

Masolini, P ;

Baccarani, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) :703-709

[7] Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate [J].

Sievers, EL ;

Appelbaum, FR ;

Spielberger, RT ;

Forman, SJ ;

Flowers, D ;

Smith, FO ;

Shannon-Dorcy, K ;

Berger, MS ;

Bernstein, ID .

BLOOD, 1999, 93 (11) :3678-3684

[8] Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells [J].

Takeshita, A ;

Shinjo, K ;

Naito, K ;

Matsui, H ;

Sahara, N ;

Shigeno, K ;

Horii, T ;

Shirai, N ;

Maekawa, M ;

Ohnishi, K ;

Naoe, T ;

Ohno, R .

LEUKEMIA, 2005, 19 (08) :1306-1311

[9] The role of gemtuzumab ozogamicin in acute leukaemia therapy [J].

Tsimberidou, AM ;

Giles, FJ ;

Estey, E ;

O'Brien, S ;

Keating, MJ ;

Kantarjian, HM .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (04) :398-409

[10] Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity [J].

Walter, RB ;

Raden, BW ;

Kamikura, DM ;

Cooper, JA ;

Bernstein, ID .

BLOOD, 2005, 105 (03) :1295-1302

← 1 2 →